Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.7 |
mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.019 | 0.7 |
mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | -0.022 | 0.7 |
mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.022 | 0.7 |
mRNA | CGP-082996 | GDSC1000 | pan-cancer | AAC | 0.021 | 0.7 |